Pfizer reaffirms commitment to COVID-19 vaccine transparency

Investing.com -- Pfizer Inc (NYSE:PFE) has reaffirmed its commitment to transparent disclosure of research findings regarding its COVID-19 vaccine while maintaining the integrity of ongoing studies.

In a statement, Pfizer Chairman and CEO Dr. Albert Bourla acknowledged Operation Warp Speed’s success under President Trump’s leadership, noting that American innovation helped prevent economic collapse and saved over 14 million lives globally.

Bourla stated that Operation Warp Speed restored consumer confidence, saved over $1 trillion in healthcare costs by reducing serious illness and hospitalizations, and rapidly scaled up domestic production. He added that the mRNA platform may drive significant innovation in cancer research.

"President Trump’s call for transparency is welcomed, and we remain deeply committed to that principle," Bourla said. "Transparency has always been a cornerstone of trust, and we are dedicated to continuing to provide clear, factual data to the public."

Pfizer highlighted that data on its COVID-19 vaccine has appeared in over 600 peer-reviewed publications and has been submitted to regulators in 130 countries, all of which approved the vaccine after review.

The company noted that several nations including the United Kingdom, Denmark, Israel, and Turkey have generated real-world evidence through their vaccination programs, further validating the vaccine’s safety and effectiveness.

In response to Trump’s request, Pfizer provided a link to its website containing published studies and safety data. The company plans to post additional information by the end of the month and will share new data about its latest FDA-approved vaccine strain in the coming days.

The announcement follows Trump’s recent social media post calling for pharmaceutical companies to justify the success of their COVID-19 vaccines and share their data with the public and CDC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.